ArticleJournal of thoracic disease2023

A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.

Wan-Qing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.